STOCKHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of AlloVir, Inc. – ALVR

Group 1 - Monteverde & Associates PC is investigating AlloVir, Inc. regarding its proposed merger with Kalaris Therapeutics [1] - Under the merger agreement, AlloVir will acquire 100% of Kalaris' outstanding equity interest [1] - Post-merger, AlloVir stockholders are expected to own approximately 25.05% of the combined company, while Kalaris stockholders are expected to own approximately 74.95% [1]